Oxagen Limited
Oxagen is a drug discovery and development company specializing in inflammation. The biopharmaceutical company is building a novel drug pipeline with a focus on inflammatory and respiratory diseases. Oxagen’s pipeline of novel small molecule drugs is based on targets validated in man. | | • Show past press releases • Edit this company
Contact Information |  |  |
Address: Phone: Fax: Web: Contact: | 91 Milton Park Abingdon OX14 4RY United Kingdom +44 (0)1235 443300 +44 (0)1235 443301 http://www.oxagen.co.uk Sue Charles +44 (0) 20 7457 2020 |
Company Facts |  |  |
Founded: | Jan 1997 | Founders: | | CEO: | Sue Charles | CTO or technical lead: | | CFO or finance director: | | Head of Sales: | | Head of Marketing: | |
| Stage: | | Category: | Biotechnology & Healthcare | Sector: | Biopharmaceuticals | Employees: | | Profitability: | | Funding raised: | Yes | Funding sought: | | Seeking Partnerships: | |
Non-executive Board Members |  |  |
Dr. David U'Prichard, President, Druid Consulting LLC Dr. Graham Boulnois, Partner, SV Lifesciences Prof. John Bell, Regius Chair of medicine, Oxford, Dura Pharmaceuticals Inc. Dr. Stuart Collinson, Partner, Forward Ventures Fund Ed Mascioli MD, Venture Partner, MPM Capital Dr. Luke Evnin, General Partner, MPM Capital
Key Customers |  |  |
not disclosed
Key Business Partners |  |  |
not disclosed
Key Competitors |  |  |
not disclosed
Capital Raised |  |  |
To view this information you must be signed in and subscribed to the online dataservice, sign in here.
To read more about the Online data service click here |
Public Offerings |  |  |
Date | Type | Exchange |
No public offerings |
|
| | Data
27,633 Tech investments From our Online Data Service
|
17,827 VC-backed companies From our Radar
|
Recent Deals
For information on Europe's most extensive database on technology funding click here!
|  |
Events
Press Releases
|